Author

Jeffery S. Loutit

Observed name: Jeff Loutit

OpenAlex ID: A5109266561

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival

2008 · David S. Alberts, Christian Marth, et al. · Gynecologic Oncology · 131

Aerosol antibiotics: considerations in pharmacological and clinical evaluation

2008 · Michael N Dudley, Jeff Loutit, et al. · Current Opinion in Biotechnology · 50

The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant Enterobacterales

2021 · Olga Lomovskaya, Debora Rubio-Aparicio, et al. · Antimicrobial Agents and Chemotherapy · 39

A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program

2018 · Mark Redell, Greg Moeck, et al. · Open Forum Infectious Diseases · 17

216. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Beta-lactamase inhibitor Xeruborbactam Alone and in Combination Meropenem in Healthy Adult Subjects

2022 · David Griffith, Jason Roberts, et al. · Open Forum Infectious Diseases · 14

401A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor RPX7009 Alone, Meropenem Alone, and both in Combination (Carbavance) TID for 7 days in Healthy Adult Subjects

2014 · David Griffith, Christopher Rubino, et al. · Open Forum Infectious Diseases · 12

Meropenem-Vaborbactam (M-V) Compared With Piperacillin-Tazobactam (P-T) in the Treatment of Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in a Phase 3 Randomized, Double-Blind, Double-Dummy Trial (TANGO 1)

2016 · Jeff Loutit, Karen Fusaro, et al. · Open Forum Infectious Diseases · 11

218. A Phase 1 Study of the Single-Dose Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor Xeruborbactam Administered as the Isobutyryloxymethyl Oral Prodrug to Healthy Adult Subjects

2022 · David Griffith, Jason Roberts, et al. · Open Forum Infectious Diseases · 9

217. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Lipopeptide QPX9003 in Healthy Adult Subjects

2022 · David Griffith, Yehuda Carmeli, et al. · Open Forum Infectious Diseases · 9

Potency of Meropenem-Vaborbactam in Lung Surfactant

2017 · Debora Rubio-Aparicio, Jeff Loutit, et al. · Antimicrobial Agents and Chemotherapy · 7

Rationale for Dose Selection for Carbavance ([CVC] Meropenem/RPX7009) in Phase 3 Trials

2015 · Olga Lomovskaya, David Griffith, et al. · Open Forum Infectious Diseases · 4

Lack of Effect of Oritavancin on Warfarin Pharmacokinetics in Healthy Adult Subjects

2016 · S. Eralp Bellibas, Carlos Sanabria, et al. · Open Forum Infectious Diseases · 2

Interference of Oritavancin on Coagulation Tests as Assessed In Vitro and in a Phase 1 Study of Normal Healthy Volunteers

2016 · Adam Belley, Richard Robson, et al. · Open Forum Infectious Diseases · 1

338Prevalence, Mortality and Outcomes of Antibiotic Therapy of Multi-Drug Resistant Acinetobacter baumannii

2014 · Kenneth T. Lapensee, Weihong Fan, et al. · Open Forum Infectious Diseases · 1

Geographic Differences in Patient Populations and Mortality due to CRE Infections: Implications for Clinical Trials of New Agents

2015 · Elizabeth Alexander, Jeff Loutit, et al. · Open Forum Infectious Diseases

Works count: 15

Citation count: 307

H-index: 9

I10-index: 7